Jonathan Tobin discusses Atox Bio's Phase 3 results and NDA submission plans


10th July 2020

Jonathan Tobin, PhD, Arix Managing Director and Atox Bio Board Director discusses Atox's Phase 3 results and planned NDA submission in Q3 2020

Stay Updated

Add your email below to stay updated with useful and informative content from Arix and our portfolio companies